文献速递乳腺癌

SERENA-6试验患者报告结局:卡米司群联合CDK4/6抑制剂用于ESR1突变晚期乳腺癌

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.
PubMed 文献 · Ann Oncol · 2025-10-20

SERENA-6试验中,一线AI+CDK4/6i治疗期间出现ESR1突变的HR阳性晚期乳腺癌患者,换用卡米司群+CDK4/6i较继续AI+CDK4/6i显著改善无进展生存并降低总体健康状况/生活质量恶化风险(HR 0.54)。本文报告患者报告结局,显示换用卡米司群+CDK4/6i延迟了疼痛、呼吸困难、情绪功能等恶化时间。

要点

  • 换用卡米司群+CDK4/6i降低疼痛恶化风险(HR 0.57,95%CI 0.37-0.86)
  • 换用卡米司群+CDK4/6i降低呼吸困难恶化风险(HR 0.52,95%CI 0.28-0.93)
  • 多数患者报告治疗副作用困扰为「完全没有」或「有一点」

核心结论

  • 在HR阳性/HER2阴性晚期乳腺癌一线AI+CDK4/6i期间出现ESR1突变的患者中,换用卡米司群+CDK4/6i较继续AI+CDK4/6i延迟了患者报告的癌症症状和功能恶化。

研究设计与样本

  • SERENA-6试验的患者报告结局分析,患者按预设时间点完成EORTC QLQ-C30、QLQ-BR23和PGI-TT问卷。
  • 所有PRO终点和分析均为预设,包括疼痛、躯体功能、乳腺症状和手臂症状至恶化时间的次要终点。

主要发现

  • EORTC QLQ-C30和QLQ-BR23基线评分在治疗组间相似。
  • 换用卡米司群+CDK4/6i较AI+CDK4/6i延迟至恶化时间并降低患者报告的癌症症状恶化风险:疼痛(HR 0.57,95%CI 0.37-0.86)、疲乏(HR 0.75,95%CI 0.46-1.24)、气短/呼吸困难(HR 0.52,95%CI 0.28-0.93)、乳腺症状(HR 0.59,95%CI 0.28-1.24)、手臂症状(HR 0.69,95%CI 0.34-1.39)。
  • 换用卡米司群+CDK4/6i较AI+CDK4/6i降低功能恶化风险:躯体功能(HR 0.74,95%CI 0.44-1.24)、角色功能(HR 0.73,95%CI 0.48-1.10)、情绪功能(HR 0.51,95%CI 0.29-0.87)。
  • 多数患者在各时间点报告对癌症治疗副作用困扰为「完全没有」或「有一点」(例如第2周:卡米司群+CDK4/6i组86% vs AI+CDK4/6i组82%)。

临床怎么用

  • 对于一线AI+CDK4/6i治疗期间出现ESR1突变的HR阳性/HER2阴性晚期乳腺癌患者,换用卡米司群+CDK4/6i可作为疾病进展前优化治疗结局的潜在新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In SERENA-6, switching from aromatase inhibitor (AI) to camizestrant with continuation of CDK4/6 inhibitor (CDK4/6i) guided by emergence of ESR1 mutations (ESR1-mut) during first-line AI-CDK4/6i in patients with hormone receptor (HR)-positive advanced breast cancer (ABC) resulted in statistically significant and clinically meaningful improvement in progression-free survival compared with AI-CDK4/6i and reduction in the risk of deterioration in global health status (GHS)/quality of life (QoL) (hazard ratio 0.54). Here we report additional data from patient-reported outcomes (PROs). PATIENTS AND METHODS: Patients completed PRO questionnaires at pre-specified timepoints, including the European Organisation for Research and Treatment of Cancer (EORTC) oncology-specific EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) and breast cancer-specific (QLQ-BR23) and Patient Global Impression of Treatment Tolerability (PGI-TT). All PRO endpoints and analyses were pre-defined, including secondary endpoints of time to deterioration (TTD) in pain, physical functioning, breast symptoms and arm symptoms. RESULTS: EORTC QLQ-C30 and EORTC QLQ-BR23 baseline scores were similar between treatment arms. Switching to camizestrant-CDK4/6i delayed TTD and reduced the risk of deterioration in patient-reported cancer symptoms [pain (hazard ratio 0.57, 95% confidence interval 0.37-0.86), fatigue (0.75, 0.46-1.24), shortness of breath/dyspnoea (0.52, 0.28-0.93), breast symptoms (0.59, 0.28-1.24) and arm symptoms (0.69, 0.34-1.39)] and functioning [physical (0.74, 0.44-1.24), role (0.73, 0.48-1.10) and emotional (0.51, 0.29-0.87)] compared with AI-CDK4/6i. Most patients reported they were 'not at all' or 'a little bit' bothered by the side effects of cancer therapy across timepoints (e.g. week 2: 86% camizestrant-CDK4/6i versus 82% AI-CDK4/6i). CONCLUSIONS: Together with the clinical efficacy and manageable safety profile of camizestrant-CDK4/6i, and reduced risk of GHS/QoL deterioration, the PROs from the SERENA-6 trial support switching to this combination as a potential new treatment strategy to optimise and improve outcomes in patients with HR-positive/HER2-negative ABC and ESR1-mut emergence, ahead of disease progression, during first-line AI-CDK4/6i.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Mayer EL, Bidard FC, Park YH, et al. Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy. Ann Oncol. 2025. PMID: 41125211. doi:10.1016/j.annonc.2025.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。